Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 04/02/12 | Statement of changes in beneficial ownership of securities |
|
1 | ||
| 02/15/12 | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions |
|
9 | ||
| 02/14/12 | Annual statement of changes in beneficial ownership of securities |
|
1 | ||
| 11/14/11 | Prospectus filed pursuant to Rule 424(b)(3) |
|
30 | ||
| 11/14/11 | Quarterly report pursuant to Section 13 or 15(d) |
|
 |
34 | |
| 08/15/11 | Prospectus filed pursuant to Rule 424(b)(3) |
|
29 | ||
| 08/15/11 | Quarterly report pursuant to Section 13 or 15(d) |
|
|
33 | |
| 08/09/11 | Prospectus filed pursuant to Rule 424(b)(3) |
|
89 | ||
| 08/08/11 | Notice of Effectiveness |
|
1 | ||
| 08/04/11 | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
1 |